151. Rasmussen encephalitis Clinical trials / Disease details
Clinical trials : 2 / Drugs : 4 - (DrugBank : 2) / Drug target genes : 6 - Drug target pathways : 86
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04003922 (ClinicalTrials.gov) | October 20, 2020 | 20/6/2019 | Study on Patients With Rasmussen Encephalitis Treated With Adalimumab: Efficacy and Tolerance in the Short and Long Term | Observational Study on Patients With Rasmussen Encephalitis Treated With Adalimumab: Efficacy and Tolerance in the Short and Long Term | Rasmussen Encephalitis | Other: Adalimumab treatment | Assistance Publique Hopitaux De Marseille | NULL | Recruiting | 2 Years | N/A | All | 40 | France | |
| 2 | NCT00545493 (ClinicalTrials.gov) | November 2002 | 16/10/2007 | Efficacy of Tacrolimus and I.V.-Immunoglobulins in Rasmussen Encephalitis | Efficacy of Tacrolimus and i.v.-Immunoglobulins in Rasmussen Encephalitis With Start of Treatment in the Acute Disease Stage. Prospective, Randomised, Open Parallel Group Study | Rasmussen Encephalitis | Drug: Tacrolimus;Drug: i.v. immunoglobulins | University Hospital, Bonn | Octapharma;Astellas Pharma GmbH | Active, not recruiting | N/A | N/A | Both | 16 | Phase 2/Phase 3 | Germany |